- Home
- PWM vs BGLC Comparison
PWM vs BGLC Comparison
Compare PWM & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- BGLC
- Stock Information
- Founded
- PWM 2018
- BGLC 2017
- Country
- PWM Hong Kong
- BGLC Malaysia
- Employees
- PWM N/A
- BGLC N/A
- Industry
- PWM
- BGLC Medical Specialities
- Sector
- PWM
- BGLC Health Care
- Exchange
- PWM Nasdaq
- BGLC Nasdaq
- Market Cap
- PWM 8.7M
- BGLC 7.6M
- IPO Year
- PWM 2023
- BGLC N/A
- Fundamental
- Price
- PWM $1.13
- BGLC $0.30
- Analyst Decision
- PWM
- BGLC
- Analyst Count
- PWM 0
- BGLC 0
- Target Price
- PWM N/A
- BGLC N/A
- AVG Volume (30 Days)
- PWM 1.2M
- BGLC 78.7K
- Earning Date
- PWM 11-29-2024
- BGLC 11-20-2024
- Dividend Yield
- PWM N/A
- BGLC N/A
- EPS Growth
- PWM N/A
- BGLC N/A
- EPS
- PWM N/A
- BGLC N/A
- Revenue
- PWM $348,528.00
- BGLC $9,183,168.00
- Revenue This Year
- PWM N/A
- BGLC N/A
- Revenue Next Year
- PWM N/A
- BGLC N/A
- P/E Ratio
- PWM N/A
- BGLC N/A
- Revenue Growth
- PWM N/A
- BGLC N/A
- 52 Week Low
- PWM $0.67
- BGLC $0.28
- 52 Week High
- PWM $3.24
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- PWM 62.01
- BGLC 24.52
- Support Level
- PWM $0.75
- BGLC $0.32
- Resistance Level
- PWM $1.25
- BGLC $0.38
- Average True Range (ATR)
- PWM 0.14
- BGLC 0.02
- MACD
- PWM 0.03
- BGLC -0.00
- Stochastic Oscillator
- PWM 75.86
- BGLC 18.27
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.